Health Notices and Appointments




2 JUNE 2011 NEW ZEALAND GAZETTE, No. 76 1795

New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturers: Lilly France SAS, Fegersheim, France
Eli Lilly Italia SpA, Florence, Italy
Product: Humalog (Vial)
Active Ingredient: Insulin lispro 100U/mL
Dosage Form: Solution for injection

New Zealand Sponsor: Eli Lilly and Company (NZ) Limited
Manufacturers: Lilly Technology Center, Indiana, United States of America
Lilly France SAS, Fegersheim, France

Product: Kliogest
Active Ingredients: Norethisterone acetate 1mg
Oestradiol hemihydrate 2.07mg
Dosage Form: Film coated tablet

New Zealand Sponsor: Novo Nordisk Pharmaceuticals Limited
Manufacturers: Novo Nordisk A/S, Copenhagen, Denmark
Novo Nordisk A/S, Måløv, Denmark

Product: Kliovance
Active Ingredients: Norethisterone acetate 0.5mg
Oestradiol hemihydrate 1.03mg equivalent to oestradiol 1mg
Dosage Form: Film coated tablet

New Zealand Sponsor: Novo Nordisk Pharmaceuticals Limited
Manufacturer: Novo Nordisk A/S, Måløv, Denmark
Product: Trisequens (Combination pack)

Kliogest Tablet
Active Ingredients: Norethisterone acetate 1mg
Oestradiol hemihydrate 2.07mg
Dosage Form: Film coated tablet

Estrofem 1mg Tablet
Active Ingredient: Oestradiol hemihydrate 1.03mg
Dosage Form: Tablet

Estrofem 2mg Tablet
Active Ingredient: Oestradiol hemihydrate 2.07mg
Dosage Form: Tablet

New Zealand Sponsor: Novo Nordisk Pharmaceuticals Limited
Manufacturer: Novo Nordisk A/S, Måløv, Denmark
Product: Vagifem
Active Ingredient: Oestradiol hemihydrate 25.8μg equivalent to oestradiol 25μg
Dosage Form: Vaginal tablet

New Zealand Sponsor: Novo Nordisk Pharmaceuticals Limited
Manufacturers: Novo Nordisk A/S, Copenhagen, Denmark
Novo Nordisk A/S, Måløv, Denmark

Dated this 26th day of May 2011.

PAT TUOHY, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).

go3645


New Zealand Public Health and Disability Act 2000

Appointment to the Cancer Control New Zealand Council

Pursuant to section 11 of the New Zealand Public Health and Disability Act 2000, I appoint

Associate Professor Jonathan Koea

as a health practitioner member of the Cancer Control New Zealand Council for a three-year term of office commencing on the date of this notification.

Dated at Wellington this 19th day of May 2011.

HON TONY RYALL, Minister of Health.

go3738

Appointment to the National Ethics Advisory Committee

Pursuant to section 11 of the New Zealand Public Health and Disability Act 2000, I appoint

Victoria Hinson

as a community representative member and chair of the National Ethics Advisory Committee for a three-year term of office commencing on the date of this notification.

Dated at Wellington this 19th day of May 2011.

HON TONY RYALL, Minister of Health.

go3740



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2011, No 76





✨ LLM interpretation of page content

🏥 Consent to the Distribution of New Medicines (continued from previous page)

🏥 Health & Social Welfare
26 May 2011
Medicines, Consent, Humalog, Kliogest, Kliovance, Trisequens, Estrofem, Vagifem
  • PAT TUOHY, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health

🏥 Appointment to the Cancer Control New Zealand Council

🏥 Health & Social Welfare
19 May 2011
Appointment, Cancer Control New Zealand Council, Health Practitioner
  • Jonathan Koea (Associate Professor), Appointed to Cancer Control New Zealand Council

  • HON TONY RYALL, Minister of Health

🏥 Appointment to the National Ethics Advisory Committee

🏥 Health & Social Welfare
19 May 2011
Appointment, National Ethics Advisory Committee, Community Representative
  • Victoria Hinson, Appointed to National Ethics Advisory Committee

  • HON TONY RYALL, Minister of Health